Avanir’s combinatorial approach to calming dementia-related outbursts among Alzheimer’s patients caught the attention of Wall Street on Monday morning. The biotech touted mid-stage data demonstrating that a match of two treatments – a generic cough suppressant and a long-approved treatment for irregular heartbeats – significantly reduced the level of agitation among the patients in the study.

READ FULL ARTICLE Curated publisher From FierceBiotech